
Puma Biotechnology (($PBYI)) has held its Q3 earnings call. Read on for the main highlights of the call. Puma Biotechnology’s third-quarter call carried a broadly positive tone, led by higher
Compare up to 40 stocks
Compared Stocks: 2 / 40
| Name | Price | % Change | |
|---|---|---|---|
| $16.40 | -2.71% | ||
| $6.98 | +47.98% |

Puma Biotechnology (($PBYI)) has held its Q3 earnings call. Read on for the main highlights of the call. Puma Biotechnology’s third-quarter call carried a broadly positive tone, led by higher

“Third quarter U.S. NERLYNX sales were positively impacted by increased year-over-year demand and were negatively impacted by higher than expected gross to net due to an increase in Medicaid and

Puma Biotechnology ($PBYI) announced an update on their ongoing clinical study. Puma Biotechnology, Inc. (PBYI) is running a Phase 2 study called “A Phase 2 Study of Alisertib in Combination

The overall interpretation of yesterday’s Fed policy decision was overwhelmingly hawkish, and yet the broadly constructive reaction in risk assets and the decline in Treasury yields served up a reminder

Puma Biotechnology (PBYI) “announced the initiation of its ALISertib in CAncer Phase II trial of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung

Puma Biotechnology (($PBYI)) has held its Q2 earnings call. Read on for the main highlights of the call. Puma Biotechnology’s latest earnings call struck a cautiously upbeat tone. Executives highlighted

TD Cowen analyst Marc Frahm raised the firm’s price target on Puma Biotechnology (PBYI) to $6 from $5 and keeps a Hold rating on the shares. The firm updated its

Reports Q2 revenue $56.5M vs $52.4M last year. “We are pleased with our commercial execution in the second quarter and the continued increase in year-over-year demand for NERLYNX. We are

Sees Q3 royalty revenue $2M-$3M, net product revenue $54M-$56M Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on

Sees FY26 net produce revenue $202M-$206M, sees FY26 royalty revenue $20M-$23M Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Reiterated | Aug 7, 2026 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.